Microviable welcomes Pilar Manrique, PhD on board
Welcome Pilar Manrique, PhD on board. Pilar obtained her undergraduate degree in Biotechnology at Universidad Francisco de Vitoria (2009) and her doctorate at Montana State University (2018). Pilar has worked over ten years studying the [...]
Microviable Therapeutics will be presenting at AIMID 2022 Meeting
Microviable Therapeutics will be presenting at I Asturias International Meeting on Clinical Microbiology and Infectious Disease (AIMID 2022) on September 22-23. Claudio Hidalgo, CEO at Microviable, will discuss the use of “Microbiome-derived biotherapeutic products for [...]
Microviable Therapeutics welcomes Ana Sañudo, PhD on board
Microviable Therapeutics welcomes Ana Sañudo, PhD on board. With a BSc degree in Biotechnology at the University of Leon (2009) and PhD at the University of Granada (2016), Ana has worked more than ten years [...]
Microviable Therapeutics welcomes our research intern Carlos Martínez.
Meet our research intern Carlos Martínez, who is working with us on his Master´s Thesis as part of the Microbiota, Probiotics and Prebiotics Master from the European University of Madrid.
Microviable will be attending AIMID 2022 (I Asturias International Meeting on Clinical Microbiology and Infectious Disease).
Microviable Therapeutics will participate and sponsor of AIMID 2022 (I Asturias International Meeting on Clinical Microbiology and Infectious Disease) that will take place in Oviedo (Asturias) on September 22-23, 2022. Microviable is honored to become [...]
Microviable Therapeutics announces Research Collaboration with the University Medical Center Utrecht and Artizan Biosciences Inc.
Gijón, 21st July 2022, Microviable Therapeutics SL, a biotechnology company in preclinical stage developing novel microbiome-derived biotherapeutic products, announced a research agreement with the University Medical Center of Utrecht (The Netherlands) and Artizan Biosciences [...]
Microviable Therapeutics announces Research Collaboration with Venter Pharma and Inmunomet Intolerancia y Disbiosis
Gijón, July 7, 2022, Microviable Therapeutics SL, a biotechnology company in preclinical stage developing novel microbiome-derived biotherapeutic products, today announced that it has entered into a research contract with Venter Pharma SL. and Inmunomet [...]
Microviable Therapeutics welcomes Manuel Arenal on board
Microviable Therapeutics welcomes Manuel Arenal on board. He has Master´s degree in Business Administration and Management at the University of Oviedo (MBA, 2015). He holds Master in Management at the ESC Clermont-Ferrand (2016) although he [...]